Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP

Phase 1 Completed 35 enrolled European Vaccine Initiative University of Oxford · collab Wellcome Trust · collab

Non-randomizedParallel-groupOpen-labelPrevention

Summary

This study examines two new malaria vaccines (FP9-PP and MVA-PP) in healthy human volunteers to determine their safety and ability to induce a measurable immune response against malaria.

Timeline

Start: 2006-04
Primary completion: —
Completion: 2007-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FP9-PP	Vaccine	—	—
Subject	MVA-PP	Vaccine	—	—

Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP

Summary

Timeline

Drugs

Indications